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Abstract: Over the last 20 years, iron oxide nanoparticles (IONPs) have been the subject of increasing
investigation due to their potential use as theranostic agents. Their unique physical properties
(physical identity), ample possibilities for surface modifications (synthetic identity), and the complex
dynamics of their interaction with biological systems (biological identity) make IONPs a unique and
fruitful resource for developing magnetic field-based therapeutic and diagnostic approaches to the
treatment of diseases such as cancer. Like all nanomaterials, IONPs also interact with different cell
types in vivo, a characteristic that ultimately determines their activity over the short and long term.
Cells of the mononuclear phagocytic system (macrophages), dendritic cells (DCs), and endothelial
cells (ECs) are engaged in the bulk of IONP encounters in the organism, and also determine IONP
biodistribution. Therefore, the biological effects that IONPs trigger in these cells (biological identity)
are of utmost importance to better understand and refine the efficacy of IONP-based theranostics.
In the present review, which is focused on anti-cancer therapy, we discuss recent findings on the
biological identities of IONPs, particularly as concerns their interactions with myeloid, endothelial,
and tumor cells. Furthermore, we thoroughly discuss current understandings of the basic molecular
mechanisms and complex interactions that govern IONP biological identity, and how these traits
could be used as a stepping stone for future research.
Keywords: iron oxide nanoparticles; nanoparticle coatings; nanoparticle–macrophage interaction;
nanoparticle–tumor cell interaction; nanoparticle–endothelial cell interaction
1. Introduction
Iron oxide nanoparticles (IONPs) belong to a family of inorganic nanomaterials that have
increasingly become the focus of research over the last decade [1,2]. When used for targeted delivery of
drugs, IONPs not only exhibit the advantages of nanoparticles such as their theranostic potential due
to a high surface-to-volume ratio and surface-stemmed chemical labile residues that allow for chemical
drug loading, but they also possess intrinsic superparamagnetic properties that permit magnetic
targeting. The superparamagnetic phenomenon occurs when the size of certain magnetic materials is
reduced below that of the single magnetic domain. For iron-based magnetic materials such as magnetite
(Fe3O4) and maghemite (Fe2O3), magnetization is not retained after removal of the external magnetic
field provided the core diameter does not exceed ~20 nm [3]. Magnetic properties such as these sparked
interest in these nanoparticles, which was then translated into the most powerful non-invasive imaging
technique available in clinical practice: magnetic resonance imaging (MRI) [4,5]. Furthermore, these
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superparamagnetic properties of IONPs also led to their application in magnetic field-driven tissue
targeting. Indeed, these features make up the physical identity of IONPs, understood as the physical
properties intrinsic to the metallic core (Table 1 and Figure 1). Physical identity ultimately determines
the biomedical application of metallic nanoparticles in imaging/therapy, and the magnetic properties
of IONPs make it possible for them to be used in MRI [5], magnetic targeting [6–8] and delivery [9,10],
and hyperthermia [11–13].
The synthetic identity of a nanomaterial refers to the properties resulting from synthesis of the
material. Synthetic identity encompasses not only the engineering of the core and surface coating
but also the final shape and size of the nanoparticle. Nanomaterials are designed to have a synthetic
identity that facilitates their intended application; for instance, ligands may be added to improve
targeting (functionalization), and PEG may be included in the coating to increase circulation time.
These physicochemical properties can therefore be manipulated to complement the physical identity of
the nanomaterial and thus improve its functionality. As a result, nanoparticle surface modifications are
key steps in developing nanoparticles for biomedical application.
The concept of nanoparticle biological identity comes into consideration when the nanomaterial is
exposed to the complex microenvironment of physiological fluids. This exposure triggers the formation
of a corona composed of biomolecules, which can lead to changes in the aggregation state and alter
the nanoparticle size. These complex interactions between the biological milieu and the nanoparticle
depend on multiple factors such as synthetic identity, the biological microenvironment, and the
interaction time with the organism. The possibility of functionalizing IONPs with biomolecules such as
peptides [14,15], ligands [16], antibodies [17,18], aptamers [19,20], or RNAs [21] further enables IONPs
to interact with a specific cell type or tissue; for instance, antibody-functionalized IONPs can specifically
target antigen-expressing tumor cells, which allows local application of an alternative magnetic field
for the induction of magnetic hyperthermia [22]. Understanding these interactions and how they
influence the intended application of the synthesized nanoparticle is critical, as such knowledge not
only allows for more rational nanomaterial design but could also enable these previously undiscovered
characteristics to be harnessed for combinatorial therapies.
As described above, both the synthetic and biological identities are integral to the nanoparticle
surface (Figure 1) and together determine the utility of nanoparticles in biomedicine. Within biological
systems, the identity of IONPs is therefore the result of effects that stem from their metallic core, their
coating, and the interaction of this coating with the biological milieu. This review will attempt to
summarize some of the common effects that IONPs display in biological systems due to their synthetic
nature. Particular focus will be on how iron oxide influences biological processes, and how this effect,
in turn, can alter myeloid, endothelial, and tumor-cell function.
Table 1. Nanoparticle identities and their outcomes.
Identity Concept
Physical This refers to the basic physical properties that define the nanoparticle core, e.g.,superparamagnetism, plasmonic, or fluorescence [23,24].
Synthetic Refers to the intrinsic physicochemical properties of the engineered surface coating, as well asits size, shape, and surface chemistry post-synthesis (surface coating modifications) [25–28].
Biological
Refers to the size and aggregation state of the nanoparticles in physiological fluids (i.e., blood,
tissue micro-environment, intracellular space) and the biomolecule (e.g., protein) corona.
Biological identity varies with changes in synthetic identity, microenvironment, and
interaction time [27–30].
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Figure 1. Iron oxide nanoparticle (IONP) identities and their relationships. (a) The core synthesis of 
IONPs provides the nanomaterial with its physical identity. For instance, the production of a small 
IONP (<20 nm) results in superparamagnetic nanoparticles. (b) The synthetic identity provides an 
added layer aimed at improving the functionality of the synthesized nanomaterial. Multiple coatings 
can be engineered on the IONP core to facilitate its application. (c) When the synthesized IONP 
interacts with physiological fluids, its properties can be altered. Referred to as the biological identity 
of the nanomaterial, this concept accounts for changes made to the colloidal status of the IONP after 
the formation of a biomolecule corona surrounding the IONP. This, in turn, can affect IONP 
endocytosis, toxicity, its detection by the immune system, or the signaling pathways that the IONP 
could trigger in cells with which it comes into contact. 
2. Iron Oxide-Driven Biological Activities: Cellular Iron Metabolism and Reactive Oxygen 
Species  
IONPs are often deemed safe due to the existence of multiple pathways in the organism that can 
process the putative excess iron produced with nanomaterial injection. Yet the possibility of systemic 
toxicity caused by an excess of iron could constitute a major drawback for the clinical application of 
IONPs. The ramifications of surplus iron are of great importance, as the possibility of such 
repercussions in healthy cells will ultimately determine the efficiency of these nanoreagents for 
Figure 1. Iron oxide nanoparticle (IONP) identities and their relationships. (a) The core synthesis of
IONPs provides the nanomaterial with its physical identity. For instance, the production of a small
IONP (<20 nm) results in superparamagnetic nanoparticles. (b) The synthetic identity provides an
added layer aimed at improving the functionality of the synthesized nanomaterial. Multiple coatings
can be engineered on the IONP core to facilitate its application. (c) When the synthesized IONP interacts
with physiological fluids, its properties can be altered. Referred to as the biological identity of the
nanomaterial, this concept accounts for changes made to the colloidal status of the IONP after the
formation of a biomolecule corona surrounding the IONP. This, in turn, can affect IONP endocytosis,
toxicity, its detection by the immune system, or the signaling pathways that the IONP could trigger in
cells with which it comes into contact.
2. Iron Oxide-Driven Biological Activities: Cellular Iron Metabolism and Reactive
Oxygen Species
IONPs are often deemed safe due to the existence of multiple pathways in the organism that
can process the putative excess iron produced with nanomaterial injection. Yet the possibility of
systemic toxicity caused by an excess of iron could constitute a major drawback for the clinical
application of IONPs. The ramifications of surplus iron are of great importance, as the possibility of
such repercussions in healthy cells will ultimately determine the efficiency of these nanoreagents for
Nanomaterials 2020, 10, 837 4 of 35
imaging/therapy. These biological effects are related to the physical identity of IONPs and thus may be
common to all iron-based nanosystems.
Based on the premise that IONP degradation products can represent an external source of iron
for the cells, the first section of this review provides an overview of the cellular mechanisms driven
by iron oxide in a physiological context. The discussion is focused on how iron oxide influences the
activity of macrophages and endothelial cells, since these cell populations come into contact with the
nanomaterial and are important regulators of iron metabolism in tissues. The influence of iron oxide
on tumor cells is also addressed. Finally, the relationship between iron oxide and reactive oxygen
species homeostasis is also presented, as it includes important mechanisms that govern the cellular
response to IONPs. This section gives an overview of the multiple cellular pathways that could be
affected by exposition to IONPs.
2.1. Cellular Components of Iron Metabolism: Macrophages
The existence of physiological iron-recycling pathways makes IONPs highly biocompatible.
Macrophages are key cells in systemic and tissue iron homeostasis [31]. Iron mobilization occurs
systemically to support erythropoiesis [32] and bacteriostatic functions [33,34]. In the local environment,
iron is mobilized from macrophages to tissues with iron need. This role relies on the metabolic
machinery orchestrated by macrophages, which balances iron intake and export with their intracellular
iron pool. Iron intake is mediated by four main pathways (Figure 2): (1) Extracellular iron is
scavenged by apo-transferrin (apo-Tf), resulting in halo-transferrin (halo-Tf), which is recognized by
the transferrin receptor (TfR1) and then endocytosed in clathrin-dependent vesicles; (2) iron-containing
heme-hemopoxin interacts with the LDR-related receptor (LRP1), which is consequently endocytosed;
(3) iron-containing hemoglobin–haptoglobin is recognized by the hemoglobin–haptoglobin receptor
(CD161) and internalized; and (4) non-Tf-bound Fe2+ is imported by the membrane-localized
transporters DMT1 (divalent metal transporter) and ZLP14 (zinc transporter ZRT/IRT-like protein-14).
Imported iron then enlarges the intracellular labile iron pool (LIP) destined for trafficking, storage,
and/or export through ferroportin-1 (FPN1) [35,36].
Most of the LIP is delivered to the mitochondrion in which Fe2+, as part of hemes and Fe–S
clusters within enzymes, assists the electron-transfer cascade and enzymatic activity. Iron cations
that are neither trafficked into mitochondria nor exported by membrane transporter FPN1 [43] are
stored by ferritin heteropolymers composed of ferritin heavy (FTH1) and ferritin light (FTL) chains.
This heteropolymer can cage up to 4500 iron atoms [44]. This complex is disassembled and degraded
by nuclear receptor coactivator 4 (NCOA4) when the LIP is low, releasing iron into the cytoplasm in
a process termed “ferritinophagy” [45,46]. Exported Fe2+ can be converted into Fe3+ by ferroxidase
enzyme ceruloplasmin (Cp), which is located extracellularly; this is a necessary step for the loading of
iron on apo-transferrin [47].
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heme oxygenase-1 (HO-1) activity that splits heme–Fe (transported by LRP1) into Fe2+ and two anti-
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Figure 2. Overview of intracellular iron metabolism in macrophages. Iron intake is mediated by 4
major pathways: (a) Extracellular iron is scavenged by apo-transferrin into halo-transferrin, which
is recognized be the transferrin receptor and internalized; (b) iron-containing heme–hemopexin is
internalized after recognition by the LRP1 receptor; (c) iron-containing hemoglobin–haptoglobin is
recognized by the CD161 receptor and internalized; and (d) non-Tf-bound iron ions (Fe2+) can be
transported from the extracellular space into the cells by the transporters DMT1 and ZIP-14. CO, carbon
monoxide; DMT-1, divalent metal transporter type 1; LIP, labile iron pool; LRP1, LDR-related receptor
type 1; NCOA, nuclear receptor coactivator 4; STEAP3, six-transmembrane epithelial antigen of the
prostate 3; ZIP-14, zinc transporter ZRT/IRT-like protein-14. Other iron sources can also contribute
to the intracellular LIP, and these comprise dying erythrocytes and other cells phagocytosed by
macrophages [37–39]. An additional source of intracellular iron is the result of the heme oxygenase-1
(HO-1) activity that splits heme–Fe (transported by LRP1) into Fe2+ and two anti-inflammatory
mediators, i.e., biliverdin and carbon monoxide (CO) [40,41]. Both of these products of heme
degradation exert an anti-inflammatory effect mediated by upregulation of IL-10, downregulation of
pro-inflammatory cytokines such as TNFα and IL-6, and downmodulation of ROS production [42].
Besides these physiological sources contributing to the intracellular LIP, the degradation products of
IONP cores can be considered as an external iron source that potentially augments intracellular iron
content. It is thus important to understand how cells could cope with this excess iron.
2.2. Cellular Components of Iron Metabolism: Endothelial Cells
In addition to macrophages, end thelial c lls also display a traffi king mechanism that supplies
iron to the local tissue environment. This is evidenced by the high density (~100,000 per cell) of
TfR found in brain icrovascular endothelial cells (BMECs), which enables these cells to sequester
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iron [48]. The entry of iron in human BMECs does not solely depend on TfR–Tf clathrin-dependent
internalization, which accounts for ~50% of the total iron internalized; rather, BMECs also rely on
the entry of non-Tf bound iron (NTBI) species mediated by cytoplasmic membrane-associated DMT1
assisted by transmembrane reductases [49]. This makes endothelial cells critical regulators of iron
transport through the blood–brain barrier (BBB) [50]. It should be noted that an increase in intracellular
Fe2+ can be detrimental to proper BMEC functioning as exemplified by the appearance of secondary
brain injuries after intracranial hemorrhage due to the excess of iron-containing factors, such as
hemoglobulin, that are released during injury [51,52]. This detrimental effect is related to the induction
of reactive oxygen species (ROS) as found by Katsu et al. [53], which is discussed in a subsequent
section of this review.
Once Tf-associated Fe3+ reaches the endosomal compartment, it is reduced to Fe2+ by a cytosolic
donor such as NAD(P)H and catalyzed by an endosomal ferrireductase, which in BMECs include
duodenal cytochrome b (Dcytb) and the six transmembrane epithelial antigen of prostate 2 (STEAP2)
(Figure 2; [49,54]). The importance of ECs in iron homeostasis is not only associated with their barrier
function; these cells also act as a sensor and play a supportive role that promotes iron accumulation
in bystander cells. Indeed, Canali et al. and Koch et al. independently found that liver sinusoidal
endothelial cells that internalize Fe2+–Tf–TfR secrete bone morphogenic protein 2 and 6 (BMP2/6),
which in turn downmodulate hepcidin expression by bystander hepatocytes. If this loop is inhibited,
overloading of iron occurs, leading to a pathological condition similar to the hemochromatosis
phenotype [55,56]. Therefore, ECs are an important regulator of iron homeostasis that connect iron
uptake (enterocytes), trafficking/recycling (macrophages), and storage (hepatocytes/erythrocytes) by
transporting iron from circulation toward tissue and modulating iron storage in bystander cells.
2.3. Iron Homeostasis and Cancer Cells
In cancer cells, iron homeostasis is often dysregulated, thus becoming a hallmark for cancer
initiation and progression. Since Richmond [57] first described the induction of sarcoma upon repetitive
intramuscular administration of an iron dextran complex, several reports demonstrated that iron can
promote carcinogenesis [58–61]. This tumorigenic property of iron appears to reflect underlying DNA
damage induced by oxidative stress [62,63].
Beyond the tumorigenic potential of iron, tumor cells also exhibit a shift in iron homeostasis toward
exacerbated intracellular iron sequestration through increasing uptake and storage, downmodulating
export, or both mechanisms. This is evidenced by the downmodulation of FPN1 and overexpression
of its natural inhibitor, hepcidin, in a variety of solid tumors, e.g., breast, ovarian, and prostate
cancer [64–68]. When disturbed, the ferroportin–hepcidin axis indeed promotes breast-tumor growth
mediated by BMP6- and IL-6-induced hepatic hepcidin, thus leading to an increase in the intracellular
LIP [69]. The involvement of the hepcidin-ferroportin-1 axis in cancer progression has been associated
not only with tumor growth but also with metastasis [70]. Epigenetic regulation mechanisms also
contribute to cancer-associated iron accumulation, including microRNA-mediated downmodulation
of ferroportin [71,72], mTOR complex 2-mediated regulation of iron-related genes via acetylation
of histone 3 [73], and hypermethylation of DNA promoter [74,75]. The capacity of tumor cells to
metabolize iron, therefore, requires consideration when developing IONP-based therapeutic strategies
for cancer.
2.4. Iron Oxide and Redox Homeostasis
Part of the effects that IONP exert on cellular function depends on the iron cation released from
the NP iron cores. Iron cations engage in cellular iron metabolism machinery and likely disturb
redox homeostasis. Reduced iron is a strong producer of reactive oxygen species (ROS) through the
Fenton reaction, whereby the electron-donor Fe2+ cation drives hydrogen peroxide (H2O2) to split
into hydroxyl anion (HO−) and the more reactive hydroxyl radical (•OH), which is able to react with
biomolecules at a diffusion-controlled rate (Equation (1) and [76,77]). The Fenton reaction remains the
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consensus explanation for the underlying mechanism that results in intracellular ROS production by
iron oxide nanoparticles, which in turn sustains hydroxyl radical production from H2O2 and potentially
disturbs redox homeostasis.
Fe2+ + H2O2→ Fe3+ + •OH + HO− (1)
Redox homeostasis is maintained by a variety of enzymatic reactions that balance the production
of intracellular H2O2 with antioxidant responses (Figure 3). The vast majority of H2O2 arises from
intracellular sources, i.e., mitochondrial superoxide dismutase (SOD2) [78], peroxisome molecular
machinery (organelle associated with lipid metabolism, [79,80]), and cytoplasmic superoxide dismutase
1 (SOD1) [81]. The main extracellular source of H2O2 is derived from the activity of superoxide
dismutase 3 (SOD3) [82].
Nanomaterials 2020, 10, x FOR PEER REVIEW 7 of 39 
 
2.4. Iron Oxide and Redox Homeostasis 
Part of the effects that IONP exert on cellular function depends on the iron cation released from 
the P iron cores. Iron cations engage in cellular iron metabolism machinery and likely disturb redox 
homeostasis. Reduced iron is a strong producer of reactive oxygen species (ROS) through the Fenton 
reaction, whereby the electron-donor Fe2+ cation drives hydrogen peroxide (H2O2) to split into 
hydroxyl anion (HO−) and the more reactive hydroxyl radical (•OH), which is able to react with 
biomolecules at a diffusion-controlled rate (Equation 1 and [76,77]). The Fenton reaction remains the 
consensus explanation for the underlying mechanism that results in intracellular ROS production by 
iron oxide nanoparticles, which in turn sustains hydroxyl radical production from H2O2 and 
potentially disturbs redox homeostasis.  
Fe2+ + H2O2 → Fe3+ + •OH + HO− (1) 
Redox homeostasis is maintained by a variety of enzymatic reactions that balance the production 
of i tracellular H2O2 with antioxidant responses (Figure 3). The vast majority of H2O2 arises fro  
intracellular sou ces, i.e., mitochondrial superoxide dismutase (SOD2) [78], eroxisome m lecular 
machinery (organelle associat d with lipid metab lism, [79,80]), an  cytoplasmic superoxide 
dismutase 1 (SOD1) [81]. The main extracellular source of H2O2 is derived from the activity of 
superoxide dismutase 3 (SOD3) [82].  
Figure 3. Overview of intracellular ROS metabolism and involvement of iron through the Fenton 
reaction. H2O2 arises from intracellular sources via the activity of cytoplasmic SOD1, mitochondrial 
SOD2, and peroxisome molecular machinery. Extracellular H2O2 is generated by extracellular SOD3. 
H2O2 production is central to the production of ROS by iron cations through the Fenton reaction. Iron 
Figure 3. Overview of intracellular ROS metabolism and involvement of iron through the Fenton
reaction. H2O2 arises from intracellular sources via the activity of cytoplasmic SOD1, mitochondrial
SOD2, and peroxisome molecular machinery. Extracellular H2O2 is generated by extracellular SOD3.
H2O2 production is central to the production of ROS by iron cations through the Fenton reaction.
Iron cations released from IONP cores drive H2O2 to split into hydroxyl anion (HO−) and the
more reactive hydroxyl radical (•OH). SOD, superoxide dismutase; CAT, catalase; UQH, reduced
ubiquinone; GSH and GSSG, reduced and oxidized glutathione, respectively; NOX, NADPH oxidase;
ER, endoplasmic reticulum.
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As a consequence of H2O2 production, a variety of cellular anti-oxidant responses are triggered
to overcome the oxidative stress and protect cellular functions, including activation of nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) and heme oxygenase-1 (HO-1) [83,84]. Nrf2 is a transcription factor
involved in the antioxidant response element (ARE)-mediated transactivation of anti-oxidant enzymes,
e.g., HO-1 and NQO-1, which reestablishes the correct cellular redox balance. Upon oxidative stress
or phosphorylation by protein kinases, Nrf2 is released from its cytoplasmatic repressor, Kelch-like
ECH-associated protein 1 (Keap1), and translocates to the nucleus where it interacts with ARE regions
within the promoter of anti-oxidant genes [85,86] (Figure 4).
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Figure 4. Overview of the ROS/Nrf2-axis and its anti-oxidant effect. Kelch-like ECH-associated protein
(KEAP1) homodimers promote NRF2 ubiquitylation leading to proteasomal degradation. KEAP1
is th n recycled to bind newly synthesized NRF2. Oxidative stress drives oxidation of key cysteine
residues on KEAP1, preventing NRF2 ubiquitylation. NRF2 can thus accumulate and translocate to
the ucleus, where it dimerizes with one of the s ll MAF proteins to promote the transcription of
anti-oxidant genes. GCLM, glutamatecysteine ligase modifier subunit; GPX, glutathione peroxidase;
KEAP1, Kelch-like ECH-associated protein 1; MAF, musculoaponeurotic fibrosarcoma; NRF2, nuclear
factor (erythroid-derived 2)-like 2.
NRF2 translocation to the nucleus also promotes the transcription of iron metabolism-associated
genes (e.g., ferroportin-1, ferritin heavy chain, ferritin light chain, Pirin). The cell thus triggers a gene
transcription program that can mitigate ROS production due to the presence of Fe2+ cations. Among
the genes regulated by NRF2, Pirin is an Fe-binding protein that can regulate the activity of NF-κB, a
master regulator of proinflammatory responses that controls immune and stress responses (Figure 5).
Pirin appears to act as a sensor of the cell redox status, which allows the NF-κB transcription factor to
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engage in DNA binding and is thought to promote NF-κB-dependent responses to oxidative stress [87].
Iron cations can, therefore, alter cellular redox homeostasis through several mechanisms. Iron cations
promote ROS production. Moreover, they can directly affect the NF-κB transcription program, likely
through their interaction with Pirin. Iron cations released from IONP cores thus have the potential to
modulate ROS production and modify immune and stress responses. IONP effects on these pathways
could be exploited to enhance the bioactivity of nanoreagents.Nanomaterials 2020, 10, x FOR PEER REVIEW 10 of 39 
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Figure 5. The ROS/Nrf2-axis regulates the labile iron pool (LIP). Iron cations are released from the
endosome/lysosome (1) and Fenton reaction-induced ROS triggers NRF2 translocation to the nucleus
and promotes the expression of iron metabolism-associated genes (ferroportin-1-FPN1-, ferritin heavy
chain-FTH1-, ferritin light chain-FTL-, and Pirin-PIR-). (2) Labile iron can be sequestered in ferritin,
which comprises FTL and FTH1 subunits. (3) Labile iron can be ex orted out of the cytosol by
ferroportin-1. (4) Labile iron can bind to PIR and influence NF-κB transcriptional activity. NRF2,
nuclear factor (erythroid-derived 2)-like 2; MAF, musculoaponeurotic fibrosarcoma.
3. Iron Oxide Nanoparticle Biodegradation
Having summarized the complex molecular and functional machinery driven by labile iron and
ROS, it becomes apparent that understanding IONP degradation is key to evaluating the biological
identity of IONPs. IONP degradation by-products can become an external source for intracellular iron
and ROS and therefore can modify cell responses. This section of the review provides an overview of
IONP biodegradation, and how this defines their biological identity. IONP degradation is dependent
on multiple factors, among which we mainly focus on the effects of the protein corona, the endocytosis
routes, and the cellular degradation machinery. These factors define how IONPs are perceived in a
biological system and co sequently how the biological system reacts to the IONPs.
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3.1. IONP Biodegradation and Biological Identity
Long term biodegradation studies have identified a loss in magnetic properties of IONPs when
inoculated [88], which correlates with a concomitant increase in iron metabolic routes consistent with a
degradation process [89]. IONP-derived iron availability depends on the endocytosis mechanisms by
which the nanoparticles enter the cells and how this internalization modulates their degradation and the
release of iron into the cytoplasm. The harsh environment found in phagolysosomes (low pH of 4.5–5),
high ionic strength, and the presence of a variety of degrading enzymes such as acid hydrolases and
cathepsins is mainly responsible for nanomaterial degradation [90–93]. From a structural point of view,
IONP degradation encompasses the targeting of three discernible physicochemical and biochemical
entities: (1) the enzymatic degradation of the protein corona that usually surrounds the nanoparticle
when it comes into contact with physiological fluids, and which determines how IONPs interact with
biological systems (biological identity); (2) degradation of the engineered surface coating (synthetic
identity); and (3) the disintegration of the metallic core (physical identity). Each step is influenced by
the nature of the material to be degraded, the cell type, and cellular metabolic status.
3.2. IONP Degradation and Protein Corona
It is nowadays accepted that IONPs adsorb a plethora of ions and biological molecules
(i.e., lipids, sugars, proteins) when they come into contact with biological fluids such as blood [94].
This biomolecular corona ultimately affects the interaction of non-functionalized IONPs with biological
systems, a property known as “biological identity”. The biomolecular corona must be taken into account
when considering the intrinsic biological effects that IONPs can produce. Indeed, Escamilla-Rivera et
al. found that PEG-coated IONPs absorb a wide variety of complement recognition proteins when
incubated with human serum, leading to complement activation when injected in mice [95]. Similarly,
Zhu et al. demonstrated that the addition of IONPs to the hyaluronic acid (HA) scaffold enhances
osteogenesis in vivo, most likely mediated by a dynamic formation of a protein corona enriched in
complement-, wound healing-, and inflammatory-related factors [96]. These reports thus suggest that
the protein corona can endow IONPs with immunomodulating features. However, the biomolecule
corona largely depends on the surface coating of the metallic core of IONPs as demonstrated by
Vogt et al. These authors found that silica-coated and dextran-coated IONPs adsorb a distinctive
subset of serum proteins, which leads to a differential effect on primary human macrophages [97].
Furthermore, the inherent dynamic nature of the protein corona, more specifically the so-called soft
corona that exhibits a high exchange rate, can affect the biological identity of IONPs. Ashby et al.
reported that a highly hydrophobic surface coating promoted the deposition of human serum proteins
having larger hydrophobic domains and a much faster exchange rate, and thus a more dynamic
protein corona. A similar correlation was found between larger core diameters and protein corona
dynamics [98]. Nanoparticle size also seems to correlate inversely with the protein corona, not only in
terms of composition but also in protein amount, due to a curvature effect [99]. Nonetheless, Ashby et al.
evidenced for the first time that a soft corona is much less influential in IONP endocytosis than a hard
corona [98]. This was demonstrated by pre-incubating amphiphilic block copolymer (AMP)-coated
IONPs of 10 and 25 nm with transferrin and assessing their endocytosis in a macrophage model. Even
when non-functionalized IONPs showed a similar internalization rate, 10-nm AMP-coated IONPs
underwent increased endocytosis by macrophages when pre-incubated with transferrin as compared
to 25-nm AMP-coated IONPs, suggesting that the presence of a hard corona is a prominent factor in
receptor-mediated endocytosis.
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Synthetic identity has a clear influence on biological identity, i.e., how the composition of the
adsorbed protein corona is determined by the nature of the surface coating (Figure 1 and Table 2).
Stepien et al. proved that two different surface coatings, i.e., glucose and polyethylene glycol (PEG),
promote the formation of protein corona with a distinct composition. These synthetic differences
also impacted the IONP degradation rate in vitro, as glucose-coated IONP degradation appeared
to be accelerated. However, in vivo assessment of biodegradation showed contrasting results, with
PEG-coated IONPs exhibiting faster biodegradation and clearance [100]. The influence of synthetic
identity on the composition of a protein corona and the biodegradation rate also leads to another
important question, i.e., how these complex interactions determine nanoparticle toxicity. Ma et al.
revealed that the nature of a corona protein determines the biodegradation rate and, consequently,
cell toxicity; the authors did this by comparing nanoparticles with three different coronae: human
serum albumin (HSA), γ-globulin, and serum fibrinogen. In their experiments, nanoparticles with
HSA-composed corona degraded faster, and as a result, cell viability decreased concomitantly with a
reduction in ATP production and mitochondrial membrane potential [101]. Lu et al. further found that
by varying the chemistry of the synthetic identity, it is possible to tailor the way proteins and NPs
interact [102]. Protein–NP interactions were found to depend on hydroxyl group availability. HSA/IgE
interaction with the NP graphene/gold surface correlated inversely with available hydroxyl groups.
ApoE interaction with these NPs was less dependent on these groups, which likely prolonged the
circulation of these ApoE-rich corona NPs when compared to their IgE-rich counterparts. Liu et al.
demonstrated that external physical cues are yet other factors that affect the protein corona composition
of IONPs [103]. When incubated in vitro with DMEM medium with 10% FBS, the protein corona
deposited on glutamine-coated IONPs decreased drastically in terms of protein amount and composition
when an external static magnetic field (SMF) was applied. This discovery has a direct consequence in
IONP-based magnetic targeting and magnetic hyperthermia, as these data indicate that the application
of the magnetic field can affect the biological identity of the IONPs. Indeed, the SMF-adjusted protein
corona diminished the immunological response driven by IONPs as measured by the quantity of
secreted cytokines by IONP-treated macrophages. These studies illustrate how interlinked the synthetic
and biological identities of NPs are and how this will affect the intrinsic biological activities of IONPs.
This is currently an active field of investigation in which our laboratory seeks to understand how
different coatings influence protein corona composition and, ultimately, affect IONP degradation.
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Table 2. List of some of the IONPs investigated for their protein corona composition. Only significantly enriched proteins are listed.
Iron Oxide Nanoparticle Physical Identity Synthetic Identity (Surface Coating) Biological Fluid Biological Identity
IONP@Glu [100] Fe3O4 Poly(maleic
anhydride-alt-1-octadecene)-EDC-glucose





IONP@PEG [100] Fe3O4 Poly(maleic
anhydride-alt-1-octadecene)-EDC-PEG
Serum protein Actin, aortic smooth muscle
Keratin, type I cytoskeletal 10
Keratin, type II cytoskeletal 7
Lysozyme C
Fructose-biphosphate aldolase
IONP@PMAO [100] Fe3O4 Poly(maleic anhydride-alt-1-octadecene) Serum protein Fibrinogen α-chain
Tubulin α-4A chain
Adenylyl cyclase-associated protein




ZW-L1@PAA-USPIONs [104] Fe3O4 ZW-L1@PAA 80% human serum α-2-Macroglobulin precursor
Apolipoprotein C-II precursor
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Table 2. Cont.
Iron Oxide Nanoparticle Physical Identity Synthetic Identity (Surface Coating) Biological Fluid Biological Identity
Rh-Citrate@ IONPs [105] Fe3O4 Rhodium citrate Human blood serum Human serum albumin
Complement C5






Fe3O4 Polyvinylpyrrolidone (PVA) or polyethylene
glycol (PEG)
Human plasma 14-3-3-Protein β/α
14-3-3-Protein ε
Protein kinase C inhibitor protein 1
78 kDa glucose-regulated protein (GRP-78)
Actin, aortic smooth muscle (α-actin-2)
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3.3. Endocytosis and IONP Degradation
The endocytic mechanisms of IONPs are often complex and involve several pathways (Table 3).
Such complexity arises from the impact of structural factors such as IONP size, charge, surface
coating, and the “biological identity”, while the cell type profoundly delineates the endocytic processes
that can take place. The protein corona also influences how IONPs are endocytosed by cells,
which in turn determines the NP intracellular fate [106–108]. Endocytosis can occur through two
main pathways in mammalian cells: (1) pinocytosis, a process that mediates the internalization
of fluids and small molecules within small vesicles (<0.15 µm) and comprises macropinocytosis,
clathrin-, caveolin-dependent, and caveolin-independent endocytosis [109–111]; and (2) phagocytosis,
a process that involves the ingestion of larger particles, e.g., microorganisms and cell debris, via larger
intracellular vesicles called phagosomes (>0.25 µm) [112–114]. Most of the pinocytic processes are
receptor-dependent, and there are key differences among them that can affect the intracellular fate of
IONPs. For instance, while caveolin-dependent endocytosis requires membrane invagination around
cholesterol-rich rafts, thus causing it to be a slow mechanism, clathrin-dependent pinocytosis is often a
fast process connected to internalization of nutrients such as iron-laden transferrin [115]. Rezai et al.
demonstrated that PVA–PLGA-NPs are internalized differently depending on dysopsonin/opsonin
abundance in the protein corona. Higher opsonin proportion favored FcR-dependent internalization,
while in FcR– cells, opsonins hampered nanoparticle internalization [27]. This ratio between dysopsonin
and opsonin could, therefore, be key not only for prolonging NP circulation, but could also be
manipulated to improve targeting towards a particular cell type or even a subcellular compartment.
Nonetheless, synthetic identity can also impact the nanoparticle uptake as elucidated by
Feng et al. [116], who compared the internalization of polyethyleneimine-coated IONPs and PEGylated
counterparts. In line with our results obtained with PEI-coated IONPs, these researchers found
that highly positive-charged IONPs are taken up at a higher rate by RAW264.7 cells as compared
to the nearly neutral-charged PEGylated IONPs. This profound influence of surface charges on
nanoparticle endocytosis has been addressed before [117], indicating that positively charged IONPs
tend to accumulate intracellularly more than their negatively charged counterparts [118], and surface
charge is directly related to the biological effects on cells [119]. More importantly, negatively charged
IONPs appear to accumulate first in endosomes and later in lysosomes, while positively charged
IONPs (e.g., PEI-coated) seem to accumulate largely in lysosomes [118]. Such behavior can indeed
influence the intracellular degradation rate of nanoparticles.
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Table 3. Examples of IONPs and the endocytic pathways that mediate IONP internalization. IONPs are defined according to their identities as referred to in Table 1.
The proposed receptors mediating their endocytosis are listed. (N.A.: not available).




Endocytic Pathways Receptors Cell Type References








FA–PEI@SPIONs Fe3O4 PEI Folic acid Clathrin-dependent Folic acid
receptor
HeLa [123]









Ferumoxides Fe3O4 Dextran N.A. Clathrin-dependent SR-A THP-1 [125]
DMSA@SPIONs Fe3O4 DMSA N.A. Clathrin-dependent (<200 nm)
and macropinocytosis
(aggregates > 200 nm)
N.A. MCF-7 [126]
Carboxydextran@USPION Fe3O4 Carboxydextran N.A. Clathrin-dependent SR-A Human
macrophages
[127]








Aminosilane@IONPs Fe3O4 Aminosilane N.A. Phagocytosis N.A. Lung cancer cell,
SPC-A1
[130]








Aminodextran@IONPs Fe3O4 Aminodextran N.A. Macropinocytosis N.A. A-549 [133]
PEI@IONPs Fe3O4 PEI N.A. Adsorptive endocytosis N.A. RAW264.7 [116]
PEG@IONPs Fe3O4 Polyethylene
glycol
N.A. Receptor-mediated endocytosis N.A. RAW264.7 [116]
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3.4. IONP Biodegradation by Cellular Machinery
Once internalized, IONPs can be degraded by cellular machinery. Ferritin plays a crucial role in
protecting cells from ROS-triggered injury upon IONP internalization by storing excess Fe3+ derived
from the nanoparticles. An increase in ferritin levels after IONP treatment was detected in vitro in
several macrophage models and in vivo in liver extracts, confirming that this iron metabolic pathway is
activated by IONP administration [89]. In vivo experiments by Maraloiu et al. reveal that maghemite
nanoparticles are degraded down to the non-toxic complex ferritin in spleen and atherosclerosis
plaques [134]. Systemically, IONP biodegradation starts with the capture of IONP as early as 3 h
post-intravenous injection, mainly by endothelial cells present in liver sinusoids and spleen capillary
as well as by Kupffer cells and macrophages in the liver and spleen. Twenty-eight days later, most
EC-associated IONP clusters disappear, and the remnants exhibit high-density packaging along with an
increment in ferritin deposits as visualized by the presence of less-dense clusters [135]. A study by Mejías
et al. presented some of the earliest evidence that the physical identity of IONPs changes once they enter
the body. They observed that the magnetic susceptibility of organs such as liver and spleen exhibited
an acute increase after 30 min due to IONP accumulation, but diminished thereafter. This change
reflected a shift in iron-core status from a superparamagnetic core to a non-superparamagnetic
form [88]. Similar behavior was observed in rats, where DMSA-coated IONPs demonstrated a faster
degradation rate as compared to PEG-coated IONPs, suggesting that synthetic identity impacts
systemic biodegradation [136]. Mazuel et al. studied IONP degradation within stem cells by measuring
the magnetic properties of IONP-loaded spheroids. The magnetic properties (magnetometry and
magnetophoresis) of human stem-cell spheroids varied over time (up to 27 days), evidencing no
changes in the total amount of intracellular iron. In cellulo IONP biodegradation was evidenced by
IONP structure loss and the appearance of ferritin cages near iron-loaded endosomes. The extensive
collapse of spheroid magnetism was accompanied by demagnetization at the single-endosome
level [92], confirming the shift towards non-superparamagnetic iron forms during biodegradation.
Using a similar system, Curcio et al. studied the intracellular biodegradation of magnetosomes, a
magnetite-based particle biosynthesized by Magnetospirillum magneticum. The authors found that by
measuring cellular sample magnetization, human stem cells gradually degraded the magnetosome
material into ferrihydrite within their lysosomal/endosomal compartment over 21 days [137]. As a
consequence, photothermal conversion of stem-cell spheroids was lowered over time. Curiously,
Curcio et al. also found that when magnetosome-loaded stem cells are cultured in 2-D, magnetization
decreased by the third day of culture but recovered after 21 days, suggesting a de novo biosynthesis of
intracellular magnetic nanoparticles, most likely out of the magnetosome degradation-derived iron
pool [137]. Electron-microscopic evidence of IONP presence in cellular degradative compartments after
internalization and changes in magnetization have thus established that IONPs are likely degraded
intracellularly in lysosomal/acidic compartments and that this results in a loss of physical properties in
the nanomaterial over time. However, studies have shown disparities in the timeframe of these events,
which could be due to differences in the nanomaterials employed.
It is reasonable to think that for IONP cores to undergo massive degradation, not only their protein
corona must be degraded but also their synthetic identity, i.e., surface coating. However, only recently
have reports begun to address such matters. Zhu et al. demonstrated that poly-(isobutylene-alt-maleic
anhydride)-graft-dodecyl (PMA)@IONPs, onto which three different dyes were covalently attached by
amide bonds, are susceptible to amide bond cleavage by fetal bovine serum, aminotransferase (AST),
and trypsin [138]. Similarly, Sée et al. demonstrated that a peptide monolayer deposited onto a gold
nanoparticle undergoes enzymatic degradation by cathepsin L when nanoparticles are endocytosed
by HeLa cells [139]. Carboxydextran coating on IONPs also undergoes lysosomal degradation by
a-glucosidase upon internalization by macrophages, as demonstrated by Lunov et al. [93]. This suggests
that multiple enzymatic activities can participate in protein corona and surface-coating degradation,
which could in turn affect the kinetics of degradation of the IONP core. Indeed, our group is currently
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focusing on understanding which lysosomal enzymes can contribute to the degradation of IONPs with
different coatings.
4. IONP Effects is Dependent on Cell Type and Status
We have discussed thus far how IONP effects depend on the biological pathways they activate
when they are internalized and degraded. These are not the sole factors that govern their biological
effects. The cell type that the IONPs encounter also dictates their effects in biological systems. In the
following sections, we summarize how IONPs can affect the biology of cells they are likely to interact
with in an antitumor therapeutic setting. IONPs interact with myeloid cells specialized in the capture of
particulate materials, such as macrophages or dendritic cells. As IONPs circulate through the vascular
system, they also encounter endothelial cells. Finally, IONP also affect the tumor microenvironment.
The following section provide an overview of how the presence of iron can affect these cell types. We
also discuss the possibility of using these intrinsic biological properties of IONPs to enhance their
activity in a therapeutic setting.
4.1. IONPs and Myeloid Cells
4.1.1. Iron Metabolism and Macrophage Polarization
The interactions and effects of metallic nanoparticles on macrophage activation have been concerns
in terms of nanomaterial imaging/therapeutic efficacy and systemic nanotoxicity [140]. Iron oxide
nanoparticles are among the most widely used nanomaterials, even in clinical settings, and thus the
study of how they interact with myeloid cells is of great importance for researchers and clinicians.
The relevance of iron in myeloid cells is exemplified by the involvement of this redox-active metal in
several essential enzymes and protein regulators, all classified as hemoproteins, which participate in key
cellular processes for macrophage activity in inflammation (e.g., NADPH oxidase 2, cyclooxygenases
1 and 2, inducible nitric oxide synthase). Macrophages are also central to the systemic trafficking of
iron [141,142]. Splenic marginal metallophilic macrophages phagocytose senescent erythrocytes and
release heme-derived iron back into circulation to support different systemic and local functions such as
pro-inflammatory and bacteriostatic response [34,143]. Macrophages retain iron during inflammation
as a result of the binding of the acute-phase protein, hepcidin, which mediates an increase in iron
uptake and the internalization and degradation of the iron export transporter of the heme-free iron
ferroportin [144,145]. A more detailed review of iron macrophages has been published elsewhere [43].
The macrophage response to iron is also affected by polarization, and in turn, iron can affect
macrophage polarization (Figure 6). Recalcati et al. found that M2 macrophages express higher amounts
of iron metabolism-related proteins, e.g., transferrin receptor (TfR1), iron-responsive proteins (IRP),
and ferroportin (Fpn), when compared to unpolarized cells, while M1 macrophages downregulated
these proteins. The M1 phenotype also endows macrophages with iron sequestration ability, while the
M2 phenotype promotes iron release [146]. Exogenous iron can promote macrophage polarization
toward an M1 phenotype through the production of ROS and, in consequence, enhance p300/CBP
acyltransferase activity and the acetylation of p53 [147]. Intracellular iron also plays a crucial role in
the M2-/M1-balance according to Agoro et al. Administration of an iron-rich diet in mice promoted the
in vivo expression of high levels of the M2 markers Arg1 and Ym1 in liver and peritoneal macrophages.
More interestingly, an iron-rich diet prevented the mice from developing an LPS-induced inflammatory
response through an M1–M2 reversion, while iron deficiency exacerbates the endotoxin-induced
inflammatory response [148]. The latter finding was also corroborated by Pagani et al. when studying
the response of iron-deprived mice to LPS challenge. These authors found that iron-deprived hepatic
and splenic macrophages expressed higher levels of IL-6 and TNF than those of healthy mice, indicating
that iron content negatively regulates M1 response [149]. Nonetheless, the role of iron in the M1–M2
balance is not consistent throughout the literature (Table 4). Hoeft et al. observed that iron overloading
aggravates LPS-induced inflammatory response in mice, most likely mediated by an increment in
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mitochondria biogenesis in iron-loaded macrophages [150]. An unrestrained M1 response has been
described for iron overloading in chronic inflammatory diseases, such as atherosclerosis and chronic
venous leg ulcers, through overproduction of hydroxyl radicals and TNFα [151]. Likewise, iron load
appears to promote a persistent M1 macrophage population in the injured spinal cord which, in
addition to TNFα expression, prevents the injury site from being properly repaired [152]. Due to the
multiple effects of iron on macrophages, IONP degradation products therefore have the potential to
alter macrophage polarization.
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Table 4. A list of IONPs recently investigated for their effect on the macrophage.
Iron Oxide Nanoparticles Physical Identity Synthetic Identity
(Surface Coating)
Cell Type Described Effects Mechanism
Carboxymaltose@Fe2O3 [153] Fe2O3 Carboxymaltose J774A.1
Primary macrophages
Inhibits LPS-induced NO




PMA@IONPs (4 and 14 nm) [154] Fe3O4 PMA Hamper cell viability
Promote extensive vacuolization




PEGylated PMA@IONPs (4 and
14 nm) [154]
Fe3O4 PEGylates PMA RAW264.7 Promote cell proliferation
Promote extensive vacuolization




PDSCE@IONPs [155] γ-Fe2O3 Polydextrose sorbitol
carboxymethyl-ether
In vivo and RAW264.7 Reduce the level of LPS-induced injury





Carboxydextran@IONPs [156] Fe3O4 Carboxydextran In vivo local
administration and J774.2
Downmodulate CD86, MHC-II, Arg1
and CD163 expression (transient)
Hamper phagocytosis (transient)
N.A.















Feraheme [158] Fe3O4 Carboxymethyl dextran Induce autophagy
Induce pro-inflammatory gene
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Table 4. Cont.
Iron Oxide Nanoparticles Physical Identity Synthetic Identity
(Surface Coating)
Cell Type Described Effects Mechanism
PEI@IONPs [121] Fe3O4
γ-Fe2O3




(IL-12, IL-1β, TNFα, etc.)
Activate macrophages (increase CD40,
CD80, CD86 and I-A/I-E)
Activate the MAPK-dependent pathway
Promote podosome formation and
reduce ECM degradation
At least part of the effects
are mediated by
production of ROS and
activation of TLR-4
Citrate@Fe3O4 of different shape
(octopod, plate, cube, sphere)
[160]





In this order: Octopod > plate > cube >
sphere
Lysosome damage, ROS




(30, 80, and 120 nm)
[161]






Fe2O3 SiO2 RAW264.7 Increase CD80, CD86 and CD64 Activate NF-κB and IRF5
Fe3O4@D-SiO2
[162]
Fe3O4 SiO2 RAW264.7 Negligible effect N.A.
DMSA@IONPs
[163]
Fe3O4 DMSA M2-like THP1
BMDMs (M2)
Induce ROS production























Fe3O4 Aminodextran M2-like THP1
BMDMs (M2)
Induce ROS production
Change Fe metabolism to an iron-replete
status
Reduce Mac3
Decrease migration but increase invasion
Activation of MAPK
signaling
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4.1.2. IONP Recognition by Macrophages and Activation
It has been proven that toll-like receptors mediate most macrophage reactions to iron oxide
nanoparticles. We have demonstrated that polyethyleneimine-coated IONPs trigger macrophage
activation, partially through TLR-4 engagement and production of ROS [121]. Autophagy is often
activated upon nanoparticle phagocytosis, as demonstrated by Jin et al., who studied the effect of
two FDA-approved iron-oxide nanoparticles, resovist and ferumoxytol [158]. The macrophage-like
cells RAW 264.7, enclosed iron oxide nanoparticles within the endosome, early autophagic vacuole
and eventually double-membrane autophagic vacuoles that contained nanoparticles, small internal
vesicles, and cellular and membrane debris. These structural changes were accompanied by the
formation of LC3 puncta and overexpression of sequestosome identified by p62/SQSTM1, an autophagy
receptor that links ubiquitinated proteins and organelles with autophagosomes [164–166]. Noticeably,
IONP-induced autophagy was mediated by the activation of the TLR4-p38-Nrf2 pathway rather than
the classical autophagy machinery dependent on ATG5/12, as pre-treatment with the TLR4 signaling
inhibitor, CLI-095, prevented IONP-loaded macrophages from exhibiting autophagic activities [158].
Another key issue for re-programmed macrophage-based therapies is related to interference by
iron oxide nanoparticles with the adequate differentiation of monocytes into mature and competent
macrophages. Vallegas et al. found out that poly(acrylic acid)-coated IONPs do not alter the viability
of monocyte-derived macrophages during differentiation, but inhibit the secretion of LPS-induced
cytokines such as IL1β, IL-6, and IL-10 [167]. Nonetheless, Dalzon et al. found that iron oxide
carboxymaltose nanoparticles, known as FERINJECT®, do not significantly modulate LPS-induced
cytokine profile in primary macrophages or hamper their ability to migrate towards a chemotactic
stimulus, suggesting a clear dependence on IONP nature for macrophage activation status [168].
A clearer effect of the IONP on myeloid cells was described by Xu et al., who observed that ferumoxytol
inhibits the suppressing functions of myeloid-derived suppressor cells (MDSCs) [169]. Contrasting
with most reports in which IONPs were shown to act as ROS inductors, ferumoxytol treatment caused a
ROS reduction in MDSCs, as evidenced by the decrease of the p47phox component of the nicotinamide
adenine dinucleotide phosphate–oxidase (NOX) complex responsible for ROS production in MDSCs.
Furthermore, ferumoxytol promotes bone marrow-derived MDSC differentiation into macrophages,
reducing the appearance of these cells during sepsis-like scenarios. As a result, ferumoxytol ameliorates
LPS-induced sepsis in mice [169].
It is equally important to understand how the different macrophage populations respond to IONP
treatment, particularly as concerns approaches intended for imaging of MRI-visible macrophages,
e.g., inflamed sites [170,171]. Each macrophage phenotype indeed expresses different factors involved
in iron metabolism, and thus exhibits divergent iron sensitivity (Figure 5 and [146]). Zini et al.
demonstrated that M2-polarized THP1 macrophages internalized significantly more IONPs than
M1-polarized and M0, leading to a higher T1 signal in M2 macrophages and a higher T2* signal in
M0 macrophages [172]. Internalized IONPs could also, in turn, exert effects on polarization and iron
metabolism. In one example, our group showed that DMSA-, APS-, and aminodextran-coated IONPs
changed iron metabolism towards an iron-sequestering status in M2-like macrophage [163].
Zhao et al. elegantly demonstrated that the FDA-approved iron oxide nanoparticle, ferumoxytol,
synergizes with the TLR3 agonist poly (I:C) in inducing macrophage activation, thereby exerting a
potent anti-tumor effect in a melanoma model [173]. Noticeably, the effect observed by these authors
comprised cell contact-dependent and -independent molecular cues mostly triggered by ROS burst
and phagocytosis of tumor cells in vitro. The synergistic effects of poly (I:C) and ferumoxytol treatment
in vivo impaired primary B16F10 tumor growth, and subsequent lung metastasis appearance more
efficiently than either treatment alone. This reduction in tumor growth correlated with an increase
in pro-inflammatory macrophages within the tumor nest. More recently, Wang et al. demonstrated
that ferumoxytol is primarily internalized by macrophages through scavenger receptors, i.e., SRI/II,
and not mediated by complement C3b, as these rather large nanoparticles (30 nm) do not exhibit C3b
deposition on their surface [174]. Taking another approach, Wang et al. proved that the intracellular
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TLR9-agonists CpG and ferumoxytol also synergize to promote an M1-like phenotype in macrophages
with anti-tumoricidal capacity [175]. While the results outlined thus far are mainly focused on the
synergy between IONPs and TLR agonists, others have demonstrated that the pro-M1/anti-tumor
properties of ferumoxytol are intrinsic to the NP. Zanganeh et al. showed that the ferumoxytol-loaded
macrophage-like cells, RAW264.7, induce apoptosis in MMTV-PyMT cancer cells mediated by Fenton
reactions [176], leading to retardation in tumor growth in vivo. More importantly, intravenous
pre-treatment with ferumoxytol protected mouse liver from KP1 tumor-cell infiltration, and this was
associated with an M1-like phenotype of infiltrating macrophages and a loss of M2-like features in
resident macrophages [176].
While studying the artificial reprogramming of macrophages for cancer cell therapy, Li Chu-Xin
et al. found that feeding macrophages with hyaluronic acid-modified iron oxide NPs (HION) or bare
iron oxide NPs (ION) triggered consistent production of ROS and pro-inflammatory cytokines [177].
Consequently, both HION-fed and ION-fed macrophages exerted an anti-tumor effect on the murine
breast-tumor cell line 4T1 in a cell contact-independent manner by inducing active caspase 3 and
inhibiting cell proliferation. The tumor microenvironment is known for its highly immunosuppressive
profile, which comprises M2 macrophage populations that sustain tumor growth while hindering
a pro-inflammatory shift [178]. This M2 macrophage population is believed to arise from resident
macrophages and bone marrow-derived monocytes engaged in M2 programming by tumor cell-derived
factors such as IL-10. Therefore, it is desirable that macrophage-based antitumor therapy not only
induces an M1 phenotype from naive macrophages, but also that it reverses the resident M2 program
into an M1 phenotype. In a related study, Chu-Xin et al. found that HION-loading provided
M1 macrophages with resistance to M2-inducing factors and triggered M2-to-M1 reversion [177].
The in vivo tumor tropism of HION also provoked a reduction in tumor growth that was most likely
due to decreased proliferation and apoptosis rates, thus indicating that this nanoreagent could be
used to directly affect tumor cell growth and/or be employed for macrophage reprogramming in the
tumor microenvironment.
Given the impact that IONPs can have on macrophage activation, it is only logical to exploit this
intrinsic activity to potentiate antigen-specific immune responses by targeting the antigen-presenting
capacity of myeloid cells. Based on this reasoning, Luo et al. synthesized PMAO (poly(maleic
anhydride-alt-1-octadecene))–PEG-coated ultra-small IONPs, onto which OVA was conjugated
covalently, assessing their efficacy as a prophylactic and therapeutic vaccine for malignant melanoma.
When used as therapy, subcutaneous injection of IONPs alone in tumor-bearing mice delayed both
primary OVA-expressing B16F10 tumor growth and the number of lung metastases; when conjugated
with OVA, however, a significantly greater inhibition was observed [179]. Interestingly, while
prophylactic injection of OVA alone delayed the appearance of OVA-expressing B16F10 tumors,
the use of OVA-PMAO-PEG@IONPs completely inhibited primary tumor growth and the onset of
metastatic lung nodules. Therefore, the influence that the variable intrinsic biological activities of
IONPs have on macrophage-activation status makes IONPs instrumental for developing combinatorial
immunotherapy approaches.
4.1.3. IONPs and Dendritic Cells (DC)
Dendritic cells (DCs) are another important cellular target for IONP-based immunomodulatory
therapies. They are the primary antigen-presenting cells in the organism and represent the link between
the innate immune system, which acts as the first line of defense by detecting external threats, and the
adaptive immune system, which responds to the pathogen by mounting immune memory responses
of exquisite specificity [180]. In their immature state, DCs scan the microenvironment for danger
using pathogen recognition receptors that bind pathogen-associated molecular patterns (PAMPs) [181].
Once an immature DC recognizes a PAMP, it becomes activated and matures into a professional
antigen-presenting cell that is capable, among other things, of priming naïve T cells. DCs are therefore
critical for mounting potent and durable immune responses to pathogens. DC theragnosis with
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IONPs thus represent an attractive approach for immunomodulation of antitumor immune responses,
although strategies need to take into consideration the activation status of the DC. Indeed, Mou et
al. found that while labeling mature DCs with IONPs does not have a significant effect on mature
DC behavior, IONP-loaded immature DCs became activated as measured by increased CD80, CD86,
and MHC-II expression. IONPs may influence the antigen-presentation function of DCs. On this
issue, Shen et al. observed that lactosylated N-alkyl-polyethyleneimine (PEI2k)-IONPs promoted DC
maturation through a mechanism involving NP-mediated induction of protective autophagy [182].
Likewise, Liu et al. demonstrated that increasing concentrations of pristine IONPs enhanced OVA
cross-presentation in a model of DC. Curiously, the positively charged aminopropyltrimethoxysilane
(APTS)-coated IONPs appeared to promote more efficient antigen cross-presentation as compared
to the negatively charged IONPs (DMSA-coated IONPs), and this was dependent on TLR-3 [183].
This adjuvant effect of IONPs was also demonstrated by Zhao et al. in an OVA-based vaccine model
by administering OVA@IONPs to OVA-expressing CT26 tumor-bearing mice, which produced a
significant delay in tumor growth [184]. Zhang et al., however, revealed that PEG-coated IONPs
disturbed mitochondrial dynamics through an increase in autophagy, and as a consequence, treated
immature DCs exhibited downregulation of co-stimulatory molecules such as CD86, CD80, and CCR7,
as well as reduced phagocytic capacity [185]. Therefore, as seen in macrophages, the effects of IONPs
on DCs is variable and depends on a plethora of factors such as IONP size, shape, and coating, as
well as DC maturation status, among others. Modulation of DC activity through IONP treatment is
therefore a promising area of research that will require continued efforts to pinpoint the critical factors
influencing IONP–DC interactions.
4.2. Iron Oxide and Functions of Endothelial Cells
Although myeloid cell interaction with IONPs is essential to understand, design, and improve
IONP-based theranostics, endothelial cells (ECs) also impact the efficacy of such approaches, as these
cells necessarily interact with IONPs when migrating to the interstitial and local microenvironment.
As major targets of oxidative stress, ECs can engage anti-oxidant mechanisms that protect them
from apoptosis. Thus, even in the presence of IONPs acting as ROS-triggering agents, ECs can
promote anti-oxidant protective mechanisms. Duan et al. demonstrated that dextran-coated IONPs
induced autophagy in human umbilical vascular endothelial cells (HUVECs), which in turn promoted
cell survival. These IONP-treated HUVECs exhibited resistance to H2O2-induced cell death [186].
Likewise, Zhang et al. found that pristine IONPs disturbed autophagy in HUVECs and exacerbated
the production of pro-inflammatory cytokines such as IL-1β and TNFα [187].
We also showed that polyethyleneimine (PEI)-coated IONPs profoundly alter EC function, which
indicated that IONP-based reagents could be designed to modulate angiogenesis. PEI-coated IONPs
disturbed the formation of focal adhesions and inhibited cell migration and in vitro tube formation
through ROS-associated responses. Consistent with these in vitro effects, in vivo administration
of PEI-coated IONPs reduced the number of vessels in a human breast cancer model [119]. ROS
also mediates polyglucose sorbitol carboxymethyether (PSC)-coated IONP-triggered induction of
epithelial-to-mesenchymal transition (EMT) in vascular ECs. Wen et al. observed that PSC-coated
IONPs reduced the formation of tubules in vitro, closely resembling what we observed with PEI-coated
IONPs; in contrast to our data, however, the authors observed enhanced EC migration [188].
It is therefore likely that the synthetic identity of IONPs also influences the EC response to these
nanoreagents. Investigating the clinically relevant contrast agent, Endorem® (dextran-coated IONPs),
and custom-made silica@IONPs, Atanina et al. observed that treatment with these nanosystems
decreased impedance, and thus integrity, of human microvascular endothelial-cell layers without
affecting their viability. The loss of EC layer integrity was accompanied by the appearance of surface
intercellular gaps and a decrease in NO production [189]. Altogether, it appears that IONPs mostly
impair EC functions, suggesting they could potentially be used as an anti-angiogenic factor. However,
just like macrophages, the EC response to IONPs depends greatly on several factors, including
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synthetic identity. Matuszak et al. proved that lauric acid-coated and BSA-stabilized IONPs are highly
internalized by ECs, leading to acute toxicity, while lauric acid/BSA-coated and dextran-coated IONPs
exhibited no evident toxicity [190]. The effects of IONPs on EC remains a somewhat underexplored
area of knowledge. Given the importance of these cells in modulating immune responses and their
presence at the interface between IONPs and the tumor environment, further insight into the intrinsic
activity of IONPs on ECs will be of great interest to improve theranostic applications.
4.3. Tumor Microenvironment and Iron Oxide Nanoparticles
At this point, we have only discussed the direct implications that IONP loading has on cells of the
mononuclear phagocytic system, dendritic cells, and endothelial cells. Nonetheless, when analyzing the
tumor microenvironment (TME), we should take into consideration its intrinsic complexity. As a mere
reminder, TME is directly linked to a plethora of biological mechanisms that support tumor initiation,
progression, and metastasis [191,192]. Processes such as proliferative [193,194], anti-apoptotic [195],
pro-angiogenic [196], and immune-suppressive [197] phenomena, as well as mechanisms related to
immune-surveillance evasion by tumors [198] greatly depend on the composition and organization
of the TME. The niche that comprises the TME is formed by immune and endothelial cells as well as
fibroblasts, and all have the potential to interact with IONPs that reach the tumor mass. Therefore,
IONPs are expected to exert a biological impact on these cells as well as the tumor cells, which are
usually the main targets of IONP-based theranostics. We have demonstrated that PEI-coated IONPs
disturbed invadosome formation by the mouse tumor cells Pan02, and, as a consequence, inhibited
tumor cell migration and invasion [122]. Moreover, these same PEI-coated IONPs altered macrophage
and endothelial-cell activity in vitro and in vivo [119,122], illustrating the feasibility of developing
nanoreagents that impair tumor cell biology, modify immune infiltration, and alter tumor angiogenesis.
The presence of iron ions can also modulate the activity of the TME. Costa da Silva et al. showed
that the presence of iron-loaded macrophages nesting in the invasive margins of non-small lung cell
tumors correlated with smaller tumor size [199]. These iron-loaded cells localized near the sites of red
blood cell (RBC) extravasation, thus pointing to RBCs as the iron source. More precisely, hemolytic
RBCs trigger a TAM polarization toward an M1-like phenotype as measured by mRNA expression
of M1 markers (Il6, Nos2, and Tnfa), and increased anti-tumor activity [199]. Costa da Silva et al.
also found that cross-linked iron oxide nanoparticles injected intravenously in Lewis lung carcinoma
(LLC)-bearing mice accumulated within F4/80 macrophages and reduced tumor growth [199]. These
findings are of substantial consequence for IONP-based cancer theragnosis [200] as they indicate that,
should IONPs accumulate within TAM in the tumor margins of inner zones, TAMs could revert their
phenotype from M2 to M1.
IONPs can also support the anti-tumor effect by enhancing antigen cross-presentation in the
tumor niche, as demonstrated by Lee et al. [201]. This enhancement was attributed to a mere increase
in antigen delivery to DCs as compared to antigen alone, and not to the intrinsic biological effects
of the carriers, SiO2@IONPs, on DC activation status. Thus, the adjuvancy of IONPs was more
physical than biological, i.e., facilitating antigen endocytosis [201]. Another study using more complex
nanocomposites in which an OVA antigen was covalently attached to IONPs showed a drastic reduction
of OVA-expressing B16 tumor-derived lung metastasis in vivo [179]. In this work, IONPs exhibited an
anti-tumor effect when injected alone, suggesting they also possess intrinsic biological activity that
mitigates tumor growth. Similarly, Zanganeh et al. showed that the FDA-approved IONP, ferumoxytol,
displayed in vivo anti-tumor effects in a mouse breast cancer model, effects which were most likely
mediated through the induction of pro-inflammatory macrophages in the TME [176]. IONPs can also
directly alter tumor biology. The therapeutic value of IONPs, therefore, should not rely solely on the
capacity of these nanoparticles to modulate the tumor cell biology, but rather should also take into
account their effects on the TME.
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5. Conclusions
IONPs have shown great potential as theranostic agents for cancer treatment and imaging. This is
due in part to their biocompatibility on account of the existence of iron metabolism in the organism,
which can eliminate the putative excess iron that results from the degradation of these nanomaterials.
As part of the antitumor focus taken in the present review, we have seen that IONPs will primarily
encounter cells of the mononuclear phagocytic system, dendritic cells, endothelial cells, and tumor
cells. The physical, synthetic (coating), and biological identity of IONPs will influence their effects on
the biology of the cells they encounter in the organism; conversely, the cell type and programming
encountered by these nanoparticles will influence the effects triggered by IONPs.
The degradation of the NP iron core can influence cellular iron metabolism, which in turn can affect
activation status. Synthetic identity, including surface modifications, is also critical for determining
IONP interaction with cell types; by way of example, the synthetic identity of IONPs can be modified
to alter the internalization mechanism of cells. Overall, some common features emerge when assessing
the cellular effects of IONPs. IONPs can (1) alter iron metabolism, (2) promote ROS production, and
(3) likely induce autophagic machinery upon internalization. These complex interactions between
the nanomaterial identities and the extra- and intra-cellular environment will ultimately define the
intrinsic biological identity of IONPs. Understanding these interactions will, in turn, allow for the
development of more rational combinatorial nanoreagents for theranostics.
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